预约演示

更新于：2025-05-07

DprE1

更新于：2025-05-07

基本信息

别名

Decaprenylphospho-beta-D-ribofuranose 2-dehydrogenase、Decaprenylphosphoryl-beta-D-ribofuranose 2'-epimerase subunit DprE1、Decaprenylphosphoryl-beta-D-ribofuranose 2'-oxidase

+ [3]

简介

Component of the DprE1-DprE2 complex that catalyzes the 2-step epimerization of decaprenyl-phospho-ribose (DPR) to decaprenyl-phospho-arabinose (DPA), a key precursor that serves as the arabinose donor required for the synthesis of cell-wall arabinans (PubMed:16291675, PubMed:19299584). DprE1 catalyzes the first step of epimerization, namely FAD-dependent oxidation of the C2' hydroxyl of DPR to yield the keto intermediate decaprenyl-phospho-2'-keto-D-arabinose (DPX) (PubMed:22733761). The intermediate DPX is then transferred to DprE2 subunit of the epimerase complex, most probably through a 'substrate channel' at the interface of DprE1-DprE2 complex (PubMed:25789990). Can also use farnesyl-phosphoryl-beta-D-ribofuranose (FPR) as substrate in vitro (PubMed:25427196). Appears to be essential for the growth and survival of M.tuberculosis (PubMed:12657046, PubMed:24517327). DprE1 is a highly vulnerable and fully validated tuberculosis drug target.

关联

项与 DprE1 相关的药物

Macozinone

靶点

DprE1

作用机制

DprE1抑制剂

在研机构

Chemical Diversity Research Institute CJSC [+2]

原研机构

École Polytechnique Fédérale de Lausanne

在研适应症

肺结核 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

TBA-7371

靶点

DprE1

作用机制

DprE1抑制剂

在研机构

Global Alliance for TB Drug Development [+4]

原研机构

阿斯利康制药有限公司

在研适应症

肺结核 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

Quabodepistat

靶点

DprE1

作用机制

DprE1抑制剂

在研机构

Otsuka Pharmaceutical Development & Commercialization, Inc. [+2]

原研机构

Otsuka Holdings Co., Ltd.

在研适应症

结核 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

项与 DprE1 相关的临床试验

CTR20251263

/ Recruiting临床1期

在中国健康参与者中评价单次与多次口服NTB-3119M片剂量递增的安全性、耐受性、药代动力学特征及食物对药代动力学影响的I期临床试验

1、评价NTB-3119M片在健康参与者中不同剂量下单次给药后的安全性与耐受性、药代动力学特征。 2、评价食物对NTB-3119M片人体内药代动力学特征的影响、安全性； 3、评价NTB-3119M片在健康参与者中不同剂量下多次给药后的安全性与耐受性、药代动力学特征。

开始日期2025-04-13

申办/合作机构

中国医学科学院药物研究所

[+1]

NCT06114628

/ Recruiting临床2期IIT

A Seamless Phase 2B/C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary Tuberculosis

The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB). The standard treatment for TB takes 24 weeks and uses four drugs. The consortium want to find new treatments that are faster but just as safe and effective.
In the trial, two new drugs will be used, BTZ-043 and GSK3036656, along with the drugs that are already used to treat TB in a variety of combinations (11 different combinations initially). These new drugs have worked well in tests with animals and have reduced the amount of TB bacteria in people's sputum/phlegm when used alone for two weeks. These new drugs will be used in combination with other TB drugs for a longer time (up to 16 weeks) in people with TB. The UNITE4TB consortium want to see if they work well and are safe.
This trial will take place at sites across the world and will involve people with TB of the lungs that would usually respond well to the standard treatment. But the new treatments being tested might also work for people with drug resistant TB, that's harder to treat.
The trial has two parts. In the first part, different combinations of drugs will be tried on up to 700 people for 16 weeks. These combinations will be compared to the standard 24-week treatment to see which ones work the best and are safe.
In the second part, the best combinations from the first part will be taken to try to find out what the best length of time is to give the treatment for. These combinations will be tried on up to 1800 people giving them either 8, 10, 12, 14 or 16 weeks treatment. The investigators will follow these people for a total of 72 weeks to make sure the treatment is working.
The UNITE4TB consortium hope that this trial will find new treatments that are fast, safe, and effective for both regular TB and resistant TB. If it works, it can then be tested again in a bigger trial to be sure.

开始日期2024-01-09

申办/合作机构

University College London

[+21]

NCT05926466

/ Recruiting临床2期IIT

A Phase IIb, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of BTZ-043 in Combination With Bedaquiline and Delamanid in Adult Subjects With Newly Diagnosed, Uncomplicated, Drug-sensitive Pulmonary Tuberculosis

This is a phase 2B, open label study, that will compare the safety and efficacy of three experimental regimens consisting of bedaquiline and delamanid in combination with different doses of BTZ-043, a novel antibiotic, in adult participants with newly diagnosed, drug-sensitive pulmonary tuberculosis. Participants will be assigned to receive either one of the three BTZ-043-containing regimens or a comparator regimen consisting of bedaquiline, delamanid and moxifloxacin. The objective is to find the optimal dose of BTZ-043 with the highest efficacy and safety to be used in subsequent studies.

开始日期2023-09-21

申办/合作机构

Ludwig-Maximilians-Universität München

[+3]

100 项与 DprE1 相关的临床结果

登录后查看更多信息

100 项与 DprE1 相关的转化医学

登录后查看更多信息

0 项与 DprE1 相关的专利（医药）

登录后查看更多信息

188

项与 DprE1 相关的文献（医药）

2025-06-01·European Journal of Pharmaceutical Sciences

DprE1 inhibitors: An insight into the recent developments and synthetic approaches

Review

作者: Naguib, Shahenda ; Elsawi, Ahmed E ; Elyamani, Mai A ; Safwat, Heba ; Negmeldin, Ahmed T ; Shahin, Mai I ; Abdel-Aziz, Hatem A ; Eldehna, Wagdy M

In the current medical era, the proliferation and dissemination of drug-resistant strains of Mycobacterium tuberculosis continue to pose a significant worldwide health hazard, necessitating the development of new and innovative medications to combat tuberculosis. Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) is a crucial enzyme for cell wall synthesis in Mycobacterium tuberculosis (Mtb). Its importance is due to its eminent contribution in forming lipoarabinomannan and arabinogalactan. The emergence of the DprE1 enzyme as a druggable target was based on inhibitors discovered in high-throughput screening. Since then, inhibitors with different types of chemical scaffolds have been reported for their activity against it. DprE1 inhibitors can be categorized according to the formation of a covalent or non-covalent bond in the enzyme's active site, causing a loss of its catalytic activity, leading to Mtb's demise. Herein, we describe diverse DprE1 inhibitors that have had anti-tubercular activity reported over the past fifteen years and till the present time.

2025-05-01·European Journal of Medicinal Chemistry

Discovery of novel pyrimidinetrione derivatives as DprE1 inhibitors with potent antimycobacterial activities

Article

作者: Li, Hua ; Liang, Jing ; Li, Yan ; Chen, Li-Xia ; Zheng, Meng-Zhu ; Liu, Yang ; Guan, Qing ; Zhang, Xiao-Lian

Tuberculosis (TB) is one of the ten major factors threatening human life and health. At present, many factors limit the application of existing anti-tuberculosis drugs, such as a small range of available drug options, poor treatment compliance, and severe toxic and side effects. It is extremely urgent to develop novel anti-tuberculosis drugs. DprE1 is a potential anti-mycobacterial cell wall target, and some DprE1 inhibitors have entered the clinical research stage. Our research group found DprE1 inhibitor G50 with similar activity as isoniazid through virtual screening in the early stage. To obtain better DprE1 inhibitors, 45 new compounds were designed and synthesized based on the structure of G50. Among them, 12 selected DprE1 enzyme inhibitors could significantly inhibit the growth of Mycobacterium tuberculosis (M.tb) H37Ra and H37Rv growth in vitro. The MIC₅₀ value of compound 42 against M.tb H37Ra is 1.071 ± 0.041 μM, with the selective index (SI) value of 186.74 (the SI value of linezolid is 119.9). Compared to G50, compound 42 exhibits a 5-fold increase in DprE1 enzyme inhibitory activity. In addition, the binding affinity of compound 42 is equivalent to that of G50. This study further enriches the examples of developing DprE1 inhibitors based on the backbone of pyrimidinetrione and also provides potential anti-tuberculosis lead compounds.

2025-04-22·Proceedings of the National Academy of Sciences

Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity

Article

作者: Ramakrishnan, Lalita ; Cook, Gregory M. ; McNeil, Matthew B. ; Edelstein, Paul H. ; Jowsey, William ; Troll, Mark ; Chrisp, Michael T. ; Cheung, Chen-Yi ; Fountain, Adam J. ; Waller, Natalie J. E.

Bedaquiline is the cornerstone of a new regimen for the treatment of drug-resistant tuberculosis. However, its clinical use is threatened by the emergence of bedaquiline-resistant strains of Mycobacterium tuberculosis . Bedaquiline targets mycobacterial ATP synthase but the predominant route to clinical bedaquiline resistance is via upregulation of the MmpS5L5 efflux pump due to mutations that inactivate the transcriptional repressor Rv0678 . Here, we show that the MmpS5L5 efflux pump reduces susceptibility to bedaquiline as well as its new, more potent derivative TBAJ-876 and other antimicrobial substrates, including clofazimine and the DprE1 inhibitors PBTZ-169 and OPC-167832. Furthermore, the increased resistance of Rv0678 mutants stems entirely from increased MmpS5L5 expression. These results highlight the potential of a pharmacological MmpS5L5 inhibitor to increase drug efficacy. Verapamil, primarily used as a calcium channel inhibitor, is known to inhibit diverse efflux pumps and to potentiate bedaquiline and clofazimine activity in M. tuberculosis . Here, we show that verapamil potentiates the activity of multiple diverse MmpS5L5 substrates. Using biochemical approaches, we demonstrate that verapamil does not exert this effect by acting as a disruptor of the protonmotive force used to power MmpS5L5, as previously proposed, suggesting that verapamil inhibits the function of the MmpS5L5 pump. Finally, norverapamil, the major verapamil metabolite, which has greatly reduced calcium channel activity, has equal potency in reducing resistance to MmpS5L5 substrates. Our findings highlight verapamil’s potential for enhancing bedaquiline TB treatment, for preventing acquired resistance to bedaquiline and other MmpS5L5 substrates, while also providing the impetus to identify additional MmpS5L5 inhibitors.

项与 DprE1 相关的新闻（医药）

2024-11-20

·药学进展

行业动态|抗结核化药1类新药NTB-3119M获批进入临床研究

“ 点击蓝字关注我们抗结核化药1类新药NTB-3119M获批进入临床研究 PPS 2024年11月11日，由青岛百洋制药有限公司与中国医学科学院药物研究所共同申报的抗结核化药1类新药NTB-3119M获得国家药品监督管理局颁发的药物临床试验批准通知书，批准开展临床试验。结核病是由结核分枝杆菌感染引起的严重危害人类健康的重大传染性疾病，多药联用的化学治疗是结核病治疗的主要手段，临床亟需安全有效的抗结核药物。作用于结核分枝杆菌细胞壁的药物是结核病治疗联合用药方案的重要组成部分，DprE1是参与结核分枝杆菌细胞壁合成的关键酶，为获得新型靶向DprE1的抗结核新药，中国医学科学院药物研究所黄海洪研究员、马辰研究员、夏学军研究员、王宝莲研究员团队以及首都医科大学附属北京胸科医院陆宇研究员团队联合研发，发现了结构新颖、抗结核活性强、成药性好的DprE1抑制剂NTB-3119M。临床前研究结果显示，NTB-3119M具有很强的体内外抗结核活性，相同剂量下具有与抗结核一线药物异烟肼相当的体内杀菌活性，展示了显著的药效学优势，是一类安全、有效、质量稳定可控的治疗结核病候选新药，有望为安全有效的结核病联合用药方案提供新选择。 NTB-3119M研发得到国家“重大新药创制”科技重大专项(2015ZX09102007-011)、中央公益性科研院所基本科研业务费(2021-YJ350-001，2018PT35026)、中国医学科学院医学与健康科技创新工程(2016-I2M-1-013)和中国药学会-以岭生物医药创新基金（CPAYLJ202007）等多方面的资金支持。文章来源：中国医学科学院药物研究所美编排版：覃冰冰文章审核：覃冰冰罗琪【免责声明】以上内容来源于互联网，不代表本平台立场或观点；如有侵犯作者著作权，请及时与我们联系（Tel：025-83271227，或直接在微信平台留言），我们将及时更正或删除。《药学进展》杂志由中国药科大学和中国药学会共同主办、国家教育部主管，中国科技核心期刊（中国科技论文统计源期刊）。刊物以反映药学科研领域的新方法、新成果、新进展、新趋势为宗旨，以综述、评述、行业发展报告为特色，以药学学科进展、技术进展、新药研发各环节技术信息为重点，是一本专注于医药科技前沿与产业动态的专业媒体。《药学进展》注重内容策划、加强组稿约稿、深度挖掘、分析药学信息资源、在药学学科进展、科研思路方法、靶点机制探讨、新药研发报告、临床用药分析、国际医药前沿等方面初具特色；特别是医药信息内容以科学前沿与国家战略需求相合，更加突出前瞻性、权威性、时效性、新颖性、系统性、实战性。根据最新统计数据，刊物篇均下载率连续三年蝉联我国医药期刊榜首，复合影响因子1.216，具有较高的影响力。《药学进展》编委会由国家重大专项化学药总师陈凯先院士担任主编，编委由新药研发技术链政府监管部门、高校科研院所、制药企业、临床医院、CRO、金融资本及知识产权相关机构近两百位极具影响力的专家组成。联系《药学进展》↓↓↓ 编辑部官网：pps.cpu.edu.cn；邮箱：yxjz@163.com；电话：025-83271227。欢迎投稿、订阅！往期推荐聚焦“兴药为民·2023生物医药创新融合发展大会”“兴药为民·2023生物医药创新融合发展大会”盛大启幕！院士专家齐聚杭城，绘就生物医药前沿赛道新蓝图“兴药强刊”青年学者论坛暨《药学进展》第二届青年编委会议成功召开“兴药为民·2023生物医药创新融合发展大会”路演专场圆满收官！校企合作新旅程已启航我知道你在看哟

临床1期临床申请

2024-03-22

·otsuka.co.jp

Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment

Otsuka Pharmaceutical, Co. Ltd. And our U.S.-based subsidiary Otsuka Pharmaceutical Development & Commercialization, Inc., announce that interim data from a Phase 2b/c trial exploring quabodepistat (QBS), in combination with delamanid and bedaquiline, for the treatment of pulmonary tuberculosis (TB) is positive and may shorten the duration of TB treatment for patients. QBS is an investigational anti-tuberculosis compound which has a new mechanism of action that interferes with the cell-wall structure of the bacteria causing TB.1,2 Worldwide, TB is the second leading infectious fatal disease after COVID-19. The interim analysis -- which was presented at the 2024 Conference on Retroviruses and Opportunistic Infections in Denver, Colorado in early March -- demonstrated that a four-month regimen of QBS, in combination with delamanid and bedaquiline, can achieve similar safety and efficacy, compared to the six-month, standard-of-care four-drug regimen in participants with drug-susceptible TB.3 These results show that sputum culture conversion rates -- or effectiveness of the treatment combination in killing the bacteria -- at the end of treatment in the pooled QBS-based, three-drug regimen arms were on par with existing standard four-drug TB treatment. The three-drug QBS-based arms were well-tolerated, with no serious treatment emergent adverse events reported, related to the regimens.3 The ongoing study, supported by Otsuka and the Bill & Melinda Gates Foundation, is being held across six clinical research sites in South Africa. Otsuka and the foundation have been collaborating to end TB worldwide, and the foundation contributed to initial funding for the early development of quabodepistat.2,3 "Otsuka is encouraged by these positive interim data and is pleased to continue working with the support of the Bill & Melinda Gates Foundation to identify safe and effective treatment options for patients living with tuberculosis," said Masanori Kawasaki, global project leader of TB Project at Otsuka Pharmaceutical. "We are deeply thankful to the patients, their families and the clinicians who participated in this important clinical research study." The trial (NCT05221502) was a multicenter, Phase 2b/c, open-label, randomized, dose-finding trial designed to evaluate the safety and efficacy of a four-month regimen of OPC-167832 (quabodepistat) in combination with delamanid and bedaquiline in patients with drug-susceptible pulmonary tuberculosis in comparison with six months standard treatment. Full results of this phase 2b/c, randomized trial are expected by the end of 2024.2,3 *1Hariguchi N et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19. *2Dawson R et al. Quabodepistat in Combination with Delamanid and Bedaquiline in Participants with Drug-Susceptible Pulmonary Tuberculosis: protocol for a multicenter, phase 2 b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy. Trials. 2024 Jan 19;25(1):70. *3Dawson R et al. A 4-month Regimen of Quabodepistat, Delamanid and Bedaquiline for Pulmonary TB: Interim Results. Conference on Retroviruses and Opportunistic Infections (CROI), 5 March 2024, Denver, Co., USA; Abstract no. 163. *4World Health Organization, Tuberculosis key facts　https://www.who.int/news-room/fact-sheets/detail/tuberculosis

临床2期临床结果临床3期

2023-06-29

·药时代

药时代BD-091项目 | 高效、低毒MerTK靶向肝癌、乳腺癌项目寻求合作

肝癌和乳腺癌是两种严重的癌症疾病，严重威胁着患者的生命和健康，肝癌具有快速生长和高度侵袭性的特点，常常在晚期才被发现；乳腺癌是女性最常见的恶性肿瘤之一，可导致乳房肿块和转移，对患者身体和心理健康造成严重影响。根据GLOBOCAN的统计，2020年全球新发乳腺癌和肝癌病例分别约为226.14万例和90.57万例，其数据在各类癌症新增病例中位居第一和第六；新增死亡病例分别为68.53万例和83.02万例，在各类癌症新增死亡病例中位居第五和第三【1】。MerTK是一种酪氨酸蛋白激酶，活性受到酪氨酸磷酸化的调节，在多种细胞类型中起着重要的生物学功能。MerTK在巨噬细胞和树突状细胞等吞噬细胞中表达，参与细胞吞噬的多个步骤的调节。在癌症治疗中，MerTK的作用被广泛研究，在某些癌症类型中起着促进肿瘤生长和进展的作用。高水平的MerTK表达被认为与乳腺癌和肝癌的增殖、侵袭、转移和耐药相关【2】。因此，靶向和抑制MerTK被认为是治疗癌症的潜在有效手段。现有机构研究开发了一类靶向酪氨酸蛋白激酶MerTK的新型抗肿瘤药物，可以高选择性地结合并抑制MerTK，阻断自噬通路，抑制肿瘤细胞的增殖和分化。研究显示，该产品抗癌效果强、毒副作用小；对靶标及MCF-7、Hep3B等细胞增殖抑制效果显著；对MCF-7异种移植瘤有明显缩瘤作用。现已初步完成了安全性评价，无明显毒副作用，并已获得国家发明专利授权，拟开发适应症为乳腺癌和肝癌。该药物目前处于临床前候选药物研发阶段，寻找潜在的项目合作或转让的机会。药时代BD团队将此项目信息发布如下。如果您对该项目有兴趣或者希望了解更多详细信息，欢迎直接与我们联系，我们将高效推进您与项目方的合作。参考文献：【1】Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.【2】Mertk: An emerging target in cancer biology and immuno-oncology项目简介项目代号：DT20230605-091药物名称：MerTK靶向抑制剂（高活性、低毒性）靶点：DprE1药物类型：小分子作用机制：该项目为喹唑啉类MerTK抑制剂，可与MerTK特异性结合，阻断自噬通路，抑制肿瘤细胞的增殖和分化。适应症：乳腺癌、肝癌产品阶段：临床前候选药物（初步完成安全性评价）合作需求：项目转让或联合开发项目优势1. 作用靶点清晰高选择性MerTK抑制剂；2. 抗癌效果强、毒副作用低对MCF-7和Hep3B等癌细胞增殖抑制效果显著；3. 市场前景广阔我国乳腺癌每年发病人数超过30万，位列女性恶性肿瘤之首；我国乳腺癌用药规模超过400亿元；靶向自噬通路的乳腺癌治疗药物市场规模增长迅速。4. 具有全球竞争力目前无靶向DprE1的非共价抑制剂上市；在靶标活性、抑菌活性、细胞毒性、抗耐药菌株活性等方面均显著优于竞品；5. 具有自主知识产权具有自主知识产权，结构新颖；与已有MerTK抑制剂的适应症不同； 6. 合成工艺简单，成本低。如果您对该项目感兴趣，欢迎与我们联系！请注明项目代号：DT20230605-091我们将与您详细探讨。谢谢！联系人：Richard电话：13817995747微信：balance002邮箱：bd@drugtimes.cn其他BD项目药时代BD-021项目 | 国外癌症疫苗公司寻求国内授权或合作研发药时代BD-009项目 | 具有独特MOA且安全、有效的美国IIb期NASH项目寻求中国权益转让药时代BD直播间第1期 | CDMO企业带产品出售药时代BD-007项目 | 潜在FIC KRas靶向的TCR项目寻求合作，转让国内/全球权益药时代BD-012项目 | 高亲和力、高效能CD24靶向单克隆抗体药时代BD-001项目 | 潜在更优THR-β激动剂，目标适应症：NASH和血脂异常。寻找全球或中国权益合作伙伴药时代BD-002项目 | 肿瘤领域潜在FIC项目寻找全球权益合作药时代BD-004项目 | 高效、高选择性，靶向CXCR4口服小分子拮抗剂转让国外权益药时代BD-029-001项目 | BIC潜质HER2/HER2双靶点抗体药时代BD-044项目 | 第三代linker技术ADC新药靶向Claudin18.2 海外公司寻求中国合作伙伴药时代BD-033项目 | FXR靶向安全有效潜在BIC小分子 NASH I期项目药时代BD-038项目 | VEGF靶向单抗III期眼病蓝海项目药时代BD-039项目 | III期抗EGFR单抗周制剂寻求合作药时代BD-034项目 | KHK靶向安全、有效BIC潜质口服小分子 NASH I期项目药时代BD-040项目 | HER2靶向FIC潜力乳腺癌一/二线疗法药时代BD-026项目 | IBS领域FIC/BIC潜质I期 5-HT3部分激动剂寻求合作药时代BD-041项目 | 高结合力、高效能PD-1xPD-L1双抗I期项目药时代BD-043项目 | 安全、高效PD-1xTGF-β双抗肿瘤项目寻求合作药时代BD-045项目 | 临床II期阶段LAT1靶向治疗脑部肿瘤及多种实体瘤的全球首创小分子药物药时代BD-056项目 | 美国临床阶段生物公司寻找投资及AD项目合作药时代BD-052项目 | FLT3靶向临床III期口服小分子寻求合作药时代BD-053项目 | 与奥贝胆酸同靶点临床II期NASH口服小分子寻求合作药时代BD-063项目 | NY-ESO-1靶点安全、有效TCR-T项目寻求合作药时代BD-035项目 | 高选择性、长半衰期PDE-5口服小分子I/II期项目寻求合作药时代BD-036项目 | DNA-PK靶向潜在FIC级别肿瘤小分子寻求合作药时代BD-065项目 | 潜在Best-In-Class腹膜透析液海外II期项目寻求合作药时代BD-066项目 | 抑郁症领域每日一次口服缓释剂寻求中国合作伙伴药时代BD-067项目 | 美国实体瘤I期GD2xCD3双抗寻求合作药时代独家代理！卡塔尔制剂药厂寻找买家！德国设计建造，去年5月份刚刚投产药时代BD-089项目 | 高选择性线粒体复合物I抑制剂血液瘤临床前项目寻求合作药时代BD-090项目 | DprE1靶向高活性、低毒性抗结核病新药寻求合作了解更多好项目，请点击阅读原文